1. Scrip
  2. >>Therapy Areas

J&J Heats Up IL-23 Inflammatory Bowel Space With Tremfya Crohn's US Filing

 
• By Kevin Grogan

AbbVie's rival interleukin-23 drug Skyrizi is now approved in the US for both principal types of inflammatory bowel disease – ulcerative colitis and Crohn’s disease. Tremfya may not be too far behind.

J&J building
• Source: Johnson & Johnson

Johnson & Johnson has made another push into the increasingly crowded interleukin-23 inflammatory bowel disease (IBD) market and filed its blockbuster Tremfya with regulators in the US for Crohn's disease.

The submission to the US Food and Drug Administration, which comes after Tremfya (guselkumab) was filed with the agency for ulcerative colitis (UC) in March, was based on the results from the Phase III GALAXI program

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.